GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Neurocrine Biosciences
Neurocrine Biosciences specializes in the treatment of neurological and endocrine diseases. Its stock price reflects the success of its key drug, Ingrezza, and the potential of its other developments. The chart below shows how commercializing a successful drug creates shareholder value.
Share prices of companies in the market segment - Neuro
Neurocrine Biosciences develops drugs for the treatment of neurological and endocrine diseases. We classify it within the Neuroscience sector. The chart below shows the overall dynamics of this segment, where clinical trial success determines valuation.
Broad Market Index - GURU.Markets
Neurocrine Biosciences is a biopharmaceutical company focused on developing drugs for the treatment of neurological and endocrine diseases. Its market capitalization earns it a spot in the GURU.Markets index. The chart below shows the overall market performance. Compare this biotech player's stock to the overall trend.
Change in the price of a company, segment, and market as a whole per day
NBIX - Daily change in the company's share price Neurocrine Biosciences
For Neurocrine, a biopharmaceutical company, daily price changes are a measure of its response to the results of clinical trials in neurology. The graph of these fluctuations is unspectacular, but they are an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Neuro
Neurocrine Biosciences, Inc. is a biotech company focused on neuroscience. This chart highlights the sector's high volatility. Comparing it to NBIX, whose success depends on its movement disorder drugs, helps assess its risk compared to more diversified companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Neurocrine Biosciences is a biopharmaceutical company focused on developing drugs for the treatment of neurological and endocrine diseases. Neuroscience is a risky field of research. The chart below illustrates the high volatility typical of the biotech sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Neurocrine Biosciences
Neurocrine is a biotech company with a successful portfolio of neuroscience drugs. Its year-over-year performance reflects both the commercial success of its existing drugs and investor confidence in its R&D platform, which is focused on new breakthrough products.
Annual dynamics of market capitalization of the market segment - Neuro
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on the treatment of neurological and endocrine diseases. Its success depends on the commercialization of key drugs and R&D results. The chart shows how its scientific achievements and market potential compare to the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Neurocrine Biosciences is a biopharmaceutical company specializing in the treatment of neurological and endocrine diseases. Its growth is driven by sales of key drugs and clinical trial success.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Neurocrine Biosciences
Neurocrine Biosciences' value depends on the success of its neuroscience drugs. The monthly fluctuations on the chart reflect sales data for its key drug, Ingrezza, for the treatment of tardive dyskinesia, as well as news about clinical trials of new drugs from its R&D pipeline.
Monthly dynamics of market capitalization of the market segment - Neuro
Neurocrine Biosciences is a biopharmaceutical company specializing in the treatment of neurological and endocrine diseases, best known for its drug Ingrezza for tardive dyskinesia. Its sector dynamics, shown in the chart, reflect R&D risks. This allows one to assess how the success of its key product and investments in new drug development shape the company's future.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Neurocrine Biosciences is a biopharmaceutical company focused on neuroscience. Its stock often moves based on clinical trial results rather than overall market sentiment. The chart below shows how lab news and FDA decisions have enabled Neurocrine to buck the market tide.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Neurocrine Biosciences
Shares of Neurocrine Biosciences, which focuses on treating neurological diseases, exhibit high volatility on a weekly basis. Short-term price movements depend on news about clinical trials of its drugs, FDA decisions, and sales data for already approved medications.
Weekly dynamics of market capitalization of the market segment - Neuro
Neurocrine and the entire neuroscience biotech sector are driven by overall investor sentiment and news of breakthroughs. The success or failure of one major study can impact the entire industry. The chart shows how the company fares against this volatile backdrop.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Neurocrine Biosciences is a biopharmaceutical company specializing in the treatment of neurological diseases. Its success depends on sales of key drugs and research results. The chart below shows how its shares are performing independently, ignoring short-term market noise.
Market capitalization of the company, segment and market as a whole
NBIX - Market capitalization of the company Neurocrine Biosciences
Neurocrine Biosciences' market capitalization is a financial assessment of the company's success in treating neurological and endocrine diseases. The chart reflects the market value of its key drug, Ingrezza, and investors' confidence in its pipeline of future developments. Its dynamics tell the story of how a scientific idea is transformed into a commercially successful product that changes patients' lives.
NBIX - Share of the company's market capitalization Neurocrine Biosciences within the market segment - Neuro
Neurocrine Biosciences is a biopharmaceutical company focused on treating neurological and endocrine diseases. Its share of its segment's market capitalization reflects the success of its key drugs and research potential. The chart demonstrates its importance as a significant player in this complex field.
Market capitalization of the market segment - Neuro
Neurocrine Biosciences specializes in diseases of the nervous system. The chart below shows the total market capitalization of the entire neuroscience sector. This is one of the most complex and promising areas in medicine. Neurocrine's success in this field demonstrates its ability to develop in-demand drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
Biotech companies that drive value on the chart often target specific diseases. Neurocrine Biosciences specializes in treating neurological and endocrine disorders. Its market capitalization is based on the success of its drugs and its pipeline of developments targeting complex brain diseases.
Book value capitalization of the company, segment and market as a whole
NBIX - Book value capitalization of the company Neurocrine Biosciences
For Neurocrine Biosciences, this chart is the tangible foundation of brain research. The growth in book value reflects investments in cutting-edge laboratories and clinical programs. These are the physical assets where the company is working to develop new drugs for the treatment of neurological and endocrine diseases.
NBIX - Share of the company's book capitalization Neurocrine Biosciences within the market segment - Neuro
Neurocrine Biosciences invests in the creation of a sophisticated scientific infrastructure. Its share of the sector's assets is determined by its modern R&D centers and laboratories for developing drugs for neurological diseases. This physical base is the foundation for its scientific breakthroughs.
Market segment balance sheet capitalization - Neuro
Neurocrine Biosciences is a biopharmaceutical company specializing in neurological diseases. Their value is created in laboratories through years of research. A book value chart shows that their physical asset base is modest, as their primary asset is drug patents.
Book value of all companies included in the broad market index - GURU.Markets
Neurocrine Biosciences' scientific breakthroughs require a substantial resource base: modern laboratories and R&D centers for developing drugs for neurological diseases. The chart below shows how the company has grown its physical scientific capital.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Neurocrine Biosciences
Neurocrine Biosciences' laboratories have a price tag. But the market values their successful drugs and the potential of new neuroscience developments. The chart shows how much faith in their science exceeds the value of their actual assets.
Market to book capitalization ratio in a market segment - Neuro
Neurocrine Biosciences is a biopharmaceutical company focused on neurological diseases. Its value is determined by the success of its drugs and the potential of new developments. The chart shows how much its patent-based market valuation exceeds its book value.
Market to book capitalization ratio for the market as a whole
Neurocrine Biosciences is a biopharmaceutical company specializing in the treatment of neurological diseases. Its market value, compared to the average in this chart, depends almost entirely on the success of its drugs, both existing and in development. Patents and intellectual property are its key assets, not laboratories.
Debts of the company, segment and market as a whole
NBIX - Company debts Neurocrine Biosciences
Neurocrine Biosciences, a biopharmaceutical company focused on neurological diseases, uses revenue from its successful drugs to fund an extensive development pipeline. This chart shows how the company manages its capital, reinvesting profits into risky but potentially breakthrough drug research.
Market segment debts - Neuro
Neurocrine Biosciences develops and markets drugs to treat neurological and endocrine diseases. The path from the lab to the pharmacy is long and expensive, and biotech companies often use capital to fund clinical trials. This chart helps understand the company's financial strategy for its risky but important mission.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Neurocrine Biosciences
Neurocrine Biosciences develops drugs to treat neurological and endocrine diseases. This chart shows the biotech company's debt load. Debt can finance clinical trials or the marketing of already approved drugs. Dependence on the success of a few key drugs makes the business risky, especially with high debt.
Market segment debt to market segment book capitalization - Neuro
Neurocrine Biosciences develops drugs to treat neurological and endocrine diseases. Biotechnology is a high-risk, high-reward industry, requiring billions in research. The chart illustrates how aggressively the sector uses debt to fund development, and how Neurocrine compares to this.
Debt to book value of all companies in the market
Neurocrine develops drugs to treat neurological diseases. The biotech financing model is unique. This chart shows the average debt load of the entire economy. It allows us to assess how Neurocrine's financial structure, dependent on R&D success, differs from that of more predictable sectors.
P/E of the company, segment and market as a whole
P/E - Neurocrine Biosciences
Neurocrine Biosciences is a biopharmaceutical company specializing in the treatment of neurological and endocrine diseases. This chart reflects the market's valuation of its key drugs, such as Ingrezza, and confidence in its research programs. High values indicate expectations for sales growth and the success of new drugs in development.
P/E of the market segment - Neuro
Neurocrine Biosciences is a biopharmaceutical company focused on treating neurological and endocrine diseases. Their success is based on a deep understanding of neuroscience and the development of drugs for previously untreatable conditions. This chart reflects the average valuation for the neuroscience sector, reflecting investor expectations for breakthroughs in brain disease treatments.
P/E of the market as a whole
Neurocrine Biosciences is a biopharmaceutical company focused on treating neurological and endocrine diseases. This chart shows general biotech trends, but NBIX prioritizes sales of its key drugs and clinical trial results. The company's valuation is determined by its scientific portfolio, not by overall market fluctuations.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Neurocrine Biosciences
Neurocrine Biosciences is a biopharmaceutical company focused on the treatment of neurological and endocrine diseases. This chart reflects market confidence in its drug portfolio, particularly for the treatment of tardive dyskinesia. The indicator's dynamics are an estimate of future sales of existing drugs and the success of clinical-stage developments.
%20P%2FE%20Neurocrine%20Biosciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Neurocrine-Biosciences&v=1772656878967 "Chart of the company's future (projected) P/E Neurocrine Biosciences")
Future (projected) P/E of the market segment - Neuro
Neurocrine Biosciences is a biopharmaceutical company focused on treating neurological and endocrinological diseases. This chart shows the company's estimated future revenue in the context of the biotech sector. It demonstrates the investor confidence in the commercial success of its key drugs and the potential of its research programs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772656878984 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Neurocrine Biosciences is a biopharmaceutical company specializing in the treatment of neurological and endocrine diseases. Against the backdrop of general market expectations, as illustrated by this chart, Neurocrine's business is driven by R&D success. The commercial success of its drugs, such as Ingrezza, and progress in clinical trials of new candidates are the main factors influencing the company's valuation.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772656879018 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Neurocrine Biosciences
Neurocrine Biosciences is a biopharmaceutical company focused on the treatment of neurological and endocrine diseases. Its success is based on the development and commercialization of drugs that address serious medical needs. This graph shows how neuroscience research translates into financial returns.
Profit of companies in the market segment - Neuro
Neurocrine Biosciences develops treatments for neurological and endocrine diseases. This chart shows profitability in the biotech sector. For NBIX, it provides market context, assessing scientific breakthroughs and the commercial potential of new drugs. The success of their research, relative to overall industry trends, determines their value.
Overall market profit
Neurocrine Biosciences is a biopharmaceutical company focused on the treatment of neurological and endocrine diseases. Its success is based on the development and commercialization of innovative drugs. The company's financial performance is independent of the overall economic cycle. This chart allows you to assess how unique growth stories in biotech can defy broader market trends.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Neurocrine Biosciences
Neurocrine Biosciences is a biopharmaceutical company focused on the treatment of neurological and endocrine diseases. The profit forecast presented here is primarily based on sales of its key drug, Ingrezza. Analysts assess the growth potential of this drug and monitor the progress of other developments in its R&D pipeline.
%20profit%20of%20the%20company%20Neurocrine%20Biosciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Neurocrine-Biosciences&v=1772656879191 "Graph of future (projected) profit of the company Neurocrine Biosciences")
Future (predicted) profit of companies in the market segment - Neuro
Neurocrine Biosciences specializes in developing treatments for neurological and endocrine diseases. Profit forecasts for this pharmaceutical segment depend on successful clinical trials and the launch of new drugs. This chart shows the collective expectations of analysts across the industry, reflecting their belief in the commercial potential of drugs for the treatment of complex brain diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772656879198 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Neurocrine Biosciences develops treatments for neurological and endocrine diseases. The company's success depends on clinical trials and regulatory approval. The market profit forecasts presented here influence the overall biotech investment landscape and the strategic decisions of major pharmaceutical partners.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772656879208 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Neurocrine Biosciences
Neurocrine Biosciences is a biopharmaceutical company specializing in the treatment of neurological and endocrine diseases. This chart shows the market's estimate of its revenue, which is heavily dependent on sales of its flagship drug, Ingrezza. This estimate reflects expectations for the drug's continued growth and the success of other drugs in development.
P/S market segment - Neuro
Neurocrine Biosciences is a biopharmaceutical company focused on treating neurological and endocrine diseases. This chart shows the industry average market capitalization to revenue ratio. It provides insight into how the market values the company's successful drug, Ingrezza, and its pipeline of developments targeting complex and poorly understood diseases.
P/S of the market as a whole
Neurocrine Biosciences is a biopharmaceutical company focused on treating neurological and endocrine diseases. Its success is driven by sales of its key drug, Ingrezza, and the development of new drugs. This chart provides a general market context for assessing investor sentiment toward innovative healthcare companies with concentrated product portfolios.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Neurocrine Biosciences
Neurocrine Biosciences is a biopharmaceutical company specializing in the treatment of neurological and endocrine diseases. This chart reflects investors' perceptions of the company's future earnings. It demonstrates their confidence in the commercial success of its drugs and the potential of its clinical trials.
%20P%2FS%20Neurocrine%20Biosciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Neurocrine-Biosciences&v=1772656879224 "The graph of the company's future (projected) P/S Neurocrine Biosciences")
Future (projected) P/S of the market segment - Neuro
Neurocrine Biosciences specializes in developing drugs for the treatment of neurological and endocrine diseases. Its success depends on the commercialization of existing products and the success of clinical trials of new ones. This chart reflects the market's assessment of its scientific portfolio and its ability to achieve leadership in its therapeutic niche.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772656879250 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Neurocrine Biosciences is a biopharmaceutical company specializing in the treatment of neurological and endocrine diseases. Their success depends on sales of existing drugs and R&D. This market optimism curve is important for Neurocrine. It influences the overall investment climate in biotech, which is important for research funding, and indirectly, the solvency of the healthcare system.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772656879285 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Neurocrine Biosciences
Neurocrine Biosciences is a biopharmaceutical company focused on treating diseases of the nervous and endocrine systems. Its key product is designed to treat movement disorders. This chart demonstrates the commercial success of its drugs. Revenue growth is directly dependent on the increase in the number of patients taking its medications and the success of clinical trials of new products.
Sales of companies in the market segment - Neuro
Neurocrine Biosciences is a biopharmaceutical company focused on the treatment of neurological and endocrine diseases. Their primary commercial success is attributed to their drug, Ingrezza, for the treatment of tardive dyskinesia. This chart clearly shows that almost all of the company's revenue is generated by sales of this single, yet highly successful, product.
Overall market sales
Neurocrine Biosciences is a biopharmaceutical company focused on developing treatments for neurological and endocrine diseases. Its success is based on scientific research and its ability to develop drugs that address unmet medical needs. This total revenue chart includes the healthcare sector, where NBIX addresses complex medical problems.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Neurocrine Biosciences
Neurocrine Biosciences is a biopharmaceutical company specializing in the treatment of neurological and endocrine diseases. This chart shows analyst sales expectations, with Ingrezza, a drug for the treatment of tardive dyskinesia, as a key driver. These forecasts are dependent on increased prescription volumes and the success of clinical trials of new drugs.
%20sales%20of%20the%20company%20Neurocrine%20Biosciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Neurocrine-Biosciences&v=1772656879347 "Schedule of future (projected) sales of the company Neurocrine Biosciences")
Future (projected) sales of companies in the market segment - Neuro
Neurocrine Biosciences is a biopharmaceutical company focused on developing treatments for neurological and endocrine diseases. This chart shows growth forecasts for the entire market for drugs treating nervous system diseases. It illustrates the potential experts believe lies in this complex yet important pharmaceutical segment.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772656879367 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Neurocrine Biosciences specializes in developing drugs for the treatment of neurological and endocrine diseases. While demand for these drugs is stable, the overall economic situation, reflected in this chart, impacts research funding. Steady growth allows the company and its partners to confidently invest in lengthy and expensive clinical trials.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772656879383 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Neurocrine Biosciences
Neurocrine Biosciences is a biopharmaceutical company specializing in the treatment of neurological diseases. This chart shows its high profitability. This profitability is driven by the success of its drugs, such as Ingrezza for the treatment of tardive dyskinesia. Patent protection and strong demand for its unique drugs enable the company to generate high net profit.
Market segment marginality - Neuro
Neurocrine Biosciences is a biopharmaceutical company specializing in the treatment of neurological and endocrine diseases. Profitability depends on the market success of its drugs, particularly its flagship product for the treatment of tardive dyskinesia. This chart shows the commercial success of their developments. Industry superiority indicates a strong market position in its niche.
Market marginality as a whole
Neurocrine Biosciences is a biopharmaceutical company specializing in the treatment of neurological and endocrine diseases. Its success depends on the commercial success of its existing drugs and the clinical trial results of new ones. This total revenue graph does not reflect the specific scientific and market factors that determine Neurocrine's future.
Employees in the company, segment and market as a whole
Number of employees in the company Neurocrine Biosciences
Neurocrine Biosciences is a biopharmaceutical company focused on treating diseases of the nervous system and endocrine disorders. This graph shows a team of scientists and clinicians working to create new drugs for conditions such as Parkinson's disease and endometriosis. Their intellectual work brings hope to patients with serious illnesses.
Share of the company's employees Neurocrine Biosciences within the market segment - Neuro
Neurocrine Biosciences is a biopharmaceutical company focused on the treatment of neurological and endocrine diseases. This indicator reflects its scientific specialization. It demonstrates the significant number of neuroscientists and clinical specialists in this complex field of medicine that Neurocrine attracts to develop innovative treatments.
Number of employees in the market segment - Neuro
Neurocrine Biosciences is a biopharmaceutical company focused on treating neurological and endocrine diseases. Developing drugs for the brain is one of the most challenging tasks in medicine. This chart shows the growing team of scientists and clinicians working to develop new treatments that could improve the lives of millions of patients.
Number of employees in the market as a whole
Neurocrine Biosciences is a biopharmaceutical company specializing in the treatment of neurological and endocrine diseases. The company's success depends on the results of clinical trials and the ability of the healthcare system to pay for innovative drugs. The growth in overall employment, reflected in this chart, supports healthcare funding through insurance premiums, facilitating patient access to Neurocrine's new medications.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Neurocrine Biosciences (NBIX)
Neurocrine Biosciences is a biopharmaceutical company specializing in neurological diseases. This chart vividly illustrates a science-driven business. The very high market capitalization per employee suggests that the company's market value is driven by its successful drugs and the pipeline of developments created by its elite team of scientists.
%20of%20the%20company%20Neurocrine%20Biosciences%20(NBIX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Neurocrine-Biosciences-NBIX&v=1772656879495 "Chart of market capitalization per employee (in thousands of dollars) of the company Neurocrine Biosciences (NBIX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Neurocrine Biosciences is a biotech company focused on neurological diseases. Its success is based on approved drugs (like Ingrezza) and strong R&D. This chart shows the industry average, illustrating the high market value per employee that a single successful drug and a focused scientific team can generate.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772656879528 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Neurocrine Biosciences is a biopharmaceutical company specializing in diseases of the nervous system. In biotech, this metric is a measure of scientific potential. Its high market capitalization per employee reflects the market valuation of its drug pipeline and developments. A small team of scientists can create a drug that generates billions of dollars.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772656879543 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Neurocrine Biosciences (NBIX)
Neurocrine Biosciences is a biotech company focused on neurological diseases, with a successful drug called Ingrezza. This chart illustrates a classic biotech success story. After years of R&D, a single, successful, patented drug generates billions in revenue, supported by a relatively small research staff and commercial team.
%20Chart%20Neurocrine%20Biosciences%20(NBIX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Neurocrine-Biosciences-NBIX&v=1772656879555 "Company Profit Per Employee (in thousands of dollars) Chart Neurocrine Biosciences (NBIX)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Neurocrine Biosciences is a biotech company focused on neuroscience (blockbuster Ingrezza). This chart shows the benchmark for "Neuro" (Biotech). In this R&D sector, the benchmark is either negative (at the R&D stage) or astronomically high. This is the "blockbuster business," where a single patent (like Ingrezza's) generates billions.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772656879572 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Neurocrine Biosciences is a biopharmaceutical company focused on treating neurological and endocrine diseases. This graph, demonstrating the value of human capital, clearly illustrates the unique nature of their business. Here, a small group of scientists can create and commercialize a unique drug generating billions in revenue, making intellectual labor incredibly productive.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772656879573 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Neurocrine Biosciences (NBIX)
Neurocrine Biosciences is a biopharmaceutical company focused on treating neurological and endocrine diseases. This chart illustrates how scientific breakthroughs translate into commercial success. High revenue per employee is a result of the presence of successful, patented drugs on the market that generate significant cash flow.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Neurocrine-Biosciences-NBIX&v=1772656879578 "Sales chart per company employee Neurocrine Biosciences (NBIX)")
Sales per employee in the market segment - Neuro
Neurocrine Biosciences is a biotech company specializing in neurological disorders (such as dyskinesia). They have successful drugs and strong R&D. This chart shows how effective their model (R&D + commercialization) is. It compares how their team of scientists and salespeople generate revenue compared to other players in the brain-focused sector.
Sales per employee for the market as a whole
Neurocrine Biosciences is a biotech company specializing in the treatment of neurological and endocrine diseases. Their lead drug treats tardive dyskinesia (a neurological disorder). This is an R&D business. This graph shows how much revenue their team generates by selling these highly specialized, high-margin drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Neurocrine Biosciences (NBIX)
Neurocrine Biosciences (NBIX) is a biotech company specializing in the treatment of neurological and endocrine diseases. Their key drug is Ingrezza (a treatment for dyskinesia). This chart shows bearish bets. The increase in shorts may indicate that investors are concerned about increased competition for Ingrezza or are unsure of the success of other drugs in development.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Neurocrine-Biosciences-NBIX&v=1772656879639 "Short Shares Chart for the Company Neurocrine Biosciences (NBIX)")
Shares shorted by market segment - Neuro
Neurocrine Biosciences (NBIX) is a biopharmaceutical company specializing in the treatment of neurological and endocrine diseases. This chart demonstrates the general skepticism in the biotech sector. It summarizes bearish bets, reflecting investor concerns about clinical trial results or industry-wide competition.
Shares shorted by the overall market
Neurocrine Biosciences (NBIX) is a biopharmaceutical company focused on treating severe neurological diseases. This chart shows the overall level of market pessimism. On the one hand, biotech is a risky sector. But on the other, when market fears rise, demand for NBIX's life-saving drugs remains strong. This makes them an interesting stock to watch during turbulent times.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Neurocrine Biosciences (NBIX)
Neurocrine Biosciences focuses on treating neurological and endocrine diseases. Their success depends on one or two key drugs. This chart shows whether the market is overheated (above 70) due to expectations of clinical trial data or, conversely, oversold (below 30) due to concerns about patent expirations or R&D setbacks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Neurocrine-Biosciences-NBIX&v=1772656879678 "RSI 14 indicator chart for the company's stock Neurocrine Biosciences (NBIX)")
RSI 14 Market Segment - Neuro
Neurocrine Biosciences is a biopharmaceutical company focused on treating neurological and endocrine diseases. Their key product, Ingrezza, is used to treat tardive dyskinesia. This chart reflects the overall sentiment in the biotech sector. It helps distinguish Neurocrine's momentum, driven by the success of its drugs, from the general industry "noise" and "overheating."
RSI 14 for the overall market
Neurocrine Biosciences is a biopharmaceutical company focused on treating neurological and endocrine diseases. Their main product treats movement disorders. This chart shows the overall risk appetite of investors. For biotechs like NBIX, this is important: market euphoria facilitates raising capital for research. During panics, the sector often suffers from a lack of funding.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NBIX (Neurocrine Biosciences)
Neurocrine Biosciences is a biopharmaceutical company focused on treating neurological and endocrine diseases. Its success is largely due to its drug, Ingrezza. This chart summarizes analyst forecasts. Their targets are based on sales growth rates of existing drugs, as well as clinical trial results for new drugs in development.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NBIX-Neurocrine-Biosciences&v=1772656879702 "A chart showing analyst consensus forecasts for the expected stock price. NBIX (Neurocrine Biosciences)")
The difference between the consensus estimate and the actual stock price NBIX (Neurocrine Biosciences)
Neurocrine Biosciences is a biopharmaceutical company focused on neurological and endocrine diseases. Its main success is its drug, Ingrezza. This chart shows the difference between the consensus estimate and the price. It reflects analyst confidence in Ingrezza's future growth and the potential of the company's R&D pipeline (new drugs).
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NBIX-Neurocrine-Biosciences&v=1772656879722 "A chart showing the difference between the consensus forecast and the actual stock price. NBIX (Neurocrine Biosciences)")
Analyst consensus forecast for stock prices by market segment - Neuro
Neurocrine Biosciences is a biopharmaceutical company focused on developing drugs for neurological and endocrine diseases. This chart shows analysts' overall expectations for the neuroscience sector. It reflects whether experts believe breakthroughs in treating complex brain diseases are possible or whether they consider the sector too risky.
Analysts' consensus forecast for the overall market share price
Neurocrine Biosciences is a biotech company focused on neuroscience (for example, drugs for dyskinesia). Their success is rooted in science. However, overall market sentiment, visible in this chart, influences risk appetite. During periods of optimism, investors are eager to fund biotech, but during downturns, the sector often comes under pressure.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Neurocrine Biosciences
Neurocrine Biosciences is a biotech company focused on neurology and endocrinology. Their success is built on Ingrezza (a treatment for tardive dyskinesia). This chart is a summary indicator of their scientific and commercial success. It reflects the sales growth rate of Ingrezza and the market valuation of their R&D pipeline, which is expected to yield their next blockbuster.
AKIMA Market Segment Index - Neuro
Neurocrine is a biotech company focused on neuroscience; its crown jewel is Ingrezza, a treatment for tardive dyskinesia (a neurological disorder). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does Neurocrine's niche dominance (and its R&D pipeline) differentiate it from the average pharma company?
The AKIM Index for the overall market
Neurocrine is a biotech company focused on neuroscience. Its key product, Ingrezza, treats tardive dyskinesia. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this innovative scientific story, rooted in the principles of biotech, compares to broader economic trends that influence investor risk appetite.
